Form 4 for BIIB Biogen
Accepted 2022-01-21 00:00:00 ET · period of report 2022-01-19 · accession 0001127602-22-001864 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-21 | 2022-01-19 | BIIB | Galdes Alphonse | EVP Pharmaceutical Oper, Tech | A - Grant | $0.00 | +658 | 5,064 | +15% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-19 | A | A | 658 | $0.00 | 5,064.13 | D | — | — | (F1) Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022. (F2) Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021. |